Phase Ib/II Study of the Gamma-Secretase Inhibitor (GSI) RO4929097 (IND #109291) in Combination With Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma

Trial Profile

Phase Ib/II Study of the Gamma-Secretase Inhibitor (GSI) RO4929097 (IND #109291) in Combination With Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Aug 2015

At a glance

  • Drugs RG 4733 (Primary) ; Cisplatin; Temozolomide; Vinblastine
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jul 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 01 Jun 2012 Planned end date changed from 1 Jun 2011 to 1 Aug 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top